Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195355 | 1.00 | GRM1 (0.48) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL1110989 | 1.00 | GRM1 (0.48) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL7864721 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL2587696 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL9578970 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL7331719 | 0.90 | GRM1 (0.45) | GRM1GRM5GRM2GRM4SLC1A2 | |
| SCHEMBL669743 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL17064232 | 0.72 | FFAR3 (0.36) | GRM1SLC1A2SLC1A1FFAR3SLC7A5 | |
| SCHEMBL23817767 | 0.70 | — | — | |
| SCHEMBL85506 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| EP-0363994-B1 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1993-09-22 | — | — | EP | claimed |
| US-5068412-A | Nervous system disorders such as treatment of epilepsy or Huntington's chorea | SUNTORY LIMITED (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| US-5068412-A | Nervous system disorders such as treatment of epilepsy or Huntington's chorea | SUNTORY LIMITED (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0363994-A3 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1991-03-27 | — | — | EP | disclosed |
| EP-0363994-A3 | (2R,3S,4S)-ALPHA-(CARBOXYCYCLOPROPYL)GLYCINE | SUNTORY LIMITED (JP) | 1991-03-27 | — | — | EP | disclosed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
| EP-0363994-A2 | (2R,3S,4S)-alpha-(carboxycyclopropyl)glycine | SUNTORY LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | GRM1 1140/4885GRM5 1319/4885GRM2 867/4885 |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | GRM1 1291/4885GRM5 3555/4885GRM2 724/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRM1 2230/4885GRM5 1785/4885GRM2 2444/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | GRM1 2230/4885GRM5 1785/4885GRM2 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.